Evidence map›Paper›PMID 38113855›Full record

ArticleCell reports methods2023

Scalable production of homogeneous cardiac organoids derived from human pluripotent stem cells.

Taijun Moriwaki, Hidenori Tani, Kotaro Haga, Yuika Morita-Umei, Yusuke Soma, Tomohiko C Umei, Otoya Sekine, Kaworu Takatsuna, Yoshikazu Kishino, Hideaki Kanazawa and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Taijun MoriwakiDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Hidenori TaniDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan; Joint Research Laboratory for Medical Innovation in Heart Disease, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Kotaro HagaDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Yuika Morita-UmeiDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan; Kanagawa Institute of Industrial Science and Technology (KISTEC), Kawasaki, Kanagawa, Japan.
Yusuke SomaDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Tomohiko C UmeiDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Otoya SekineDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Kaworu TakatsunaDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Yoshikazu KishinoDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Hideaki KanazawaDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Jun FujitaDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan; Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA.
Keiichi FukudaDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Shugo TohyamaDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan. Electronic address: shugotohyama@keio.jp.
Masaki IedaDepartment of Cardiology, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Keio University · JPBaylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three-dimensional (3D) cultures are known to more closely mimic in vivo conditions compared with 2D cultures. Cardiac spheroids (CSs) and organoids (COs) are useful for 3D tissue engineering and are advantageous for their simplicity and mass production for regenerative therapy and drug discovery. Herein, we describe a large-scale method for producing homogeneous human induced pluripotent stem cell (hiPSC)-derived CSs (hiPSC-CSs) and COs without scaffolds using a porous 3D microwell substratum with a suction system. Our method has many advantages, such as increased efficiency and improved functionality, homogeneity, and sphericity of hiPSC-CSs. Moreover, we have developed a substratum on a clinically relevant large scale for regenerative therapy and have succeeded in producing approximately 40,000 hiPSC-CSs with high sphericity at once. Furthermore, we efficiently produced a fused CO model consisting of hiPSC-derived atrial and ventricular cardiomyocytes localized on opposite sides of one organoid. This method will facilitate progress toward hiPSC-based clinical applications.

Indexed as

Induced Pluripotent Stem CellsHeart AtriaHumansMyocytes, CardiacOrganoidsTissue Engineeringcardiac organoidscardiac spheroidsCP: Stem celldrug discoveryhuman induced pluripotent stem cellslarge-scale cultureregenerative therapy

Identifiers

PMID38113855
PMCPMC10753388
OpenAlexW4389891844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.